Articles

ASH 2019 - Chronic Lymphocytic Leukemia

Pooled Analysis of Ibrutinib versus Prior Regimen in Relapsed/Refractory Mantle-Cell Lymphoma with up to 7.5 Years of Extended Follow-Up

ASH 2019 - Chronic Lymphocytic Leukemia

Alliance A041702 Phase 3 Study Comparing Ibrutinib + Obinutuzumab versus Ibrutinib + Venetoclax + Obinutuzumab in Untreated, Older Patients with CLL

ASH 2019 - Chronic Lymphocytic Leukemia

Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia

ASH 2019 - Chronic Lymphocytic Leukemia

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53

Original Research, Practice Management

The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population

Nihar R. Desai, MD, MPH; Pamala Reed, DrPH, MPH; Paula J. Alvarez, RPh, MBA, MPH; Jeanene Fogli, PhD, RD; Steven D. Woods, PharmD; Mary Kay Owens, RPh, CPh

Stakeholder Perspective

The Impact of Quality Care on a Medicaid Population with Hyperkalemia

Byron C. Scott, MD, MBA

FDA Approvals

FDA Oncology Update

Perspectives

Predicting Success in Population Health

David B. Nash, MD, MBA

Original Research, Practice Management

Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia

David Campbell, PharmD, MS; Marlo Blazer, PharmD, BCOP; Lisa Bloudek, PharmD, MS; John Brokars, MS; Dinara Makenbaeva, MD, MBA

Stakeholder Perspective

The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs

James T. Kenney, RPh, MBA

Practice Management

Key Trends in Healthcare for 2020 and Beyond

F. Randy Vogenberg, PhD; John Santilli, MBA

ASH 2019 - Chronic Lymphocytic Leukemia

Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial

Page 43 of 244
Results 421 - 430 of 2434

Articles

Subscribe Today!

I'd like to receive: